Empower Aesthetics announced a partnership with Georgous Aesthetic Bar (pronounced "George-Us"), a nationally recognized medical spa specializing in non-surgical medical aesthetics treatments intended to elevate natural beauty and promote graceful ageing. Empower Aesthetics was formed by Shore Capital Partners ("Shore" or "Shore Capital"), a Chicago-based private equity firm focused on microcap investing. Under the leadership of Chief Executive Officer, Alyssa Rapp, and Empower's Board of Directors, this announcement marks the latest in a series of new partnerships Empower has solidified this year with leading medical aesthetics practices across the U.S.
Georgous Aesthetic Bar, founded in 2019 in Kansas City by mother-daughter duo, Georgia and Mary Kate Cirese, provides a variety of science-backed cosmetic procedures and treatments including: Botox injectables, Juvéderm filler, Diamond Glow Facial Treatment, BootYLIFT, and more, all performed by certified experts in a comfortable and inviting space. With a focus on cultivating a patient experience that doesn't feel "clinical," Georgia and Mary Kate promote a patient-first approach using treatments that are undetectable and deliver natural results. By leveraging Empower's resources and industry expertise, Georgous Aesthetics Bar is poised to rapidly scale alongside Empower's growing portfolio of clinical partners. "It's incredibly fulfilling to be able to work alongside my daughter in doing what I love each day while leaving a lasting positive impact on the lives of our patients," says Georgia Cirese. "With the additional support of the Empower Aesthetics platform and its executives, we intend on elevating our patient experience to benefit all those who have come to rely on Georgous Aesthetic Bar here, locally."
Empower's partnership with Georgous Aesthetic Bar reflects its commitment to supporting innovative and growth-driven entrepreneurs in aesthetic medicine. By building a trusted network of clinical experts, Empower aims to promote best practices and improve patient outcomes as the industry evolves.